In this trial involving patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone. (Funded by the National Cancer Institute and others; GOG-0213 ClinicalTrials.gov number, NCT00565851.).
No takes yet. Share an insight, caveat, or question.
Coleman et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: